Related Experiment Video
Updated: Jan 16, 2026

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
Published on: October 6, 2019
Interferon Regulator Factor 5: A Novel Inflammatory Marker and Promising Therapeutic Target in Ulcerative Colitis
Karima Farrag1, Aysegül Aksan2, Marina Korotkova3,4
1Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60594 Frankfurt am Main, Germany.
Interferon regulatory factor 5 (IRF5) is elevated in ulcerative colitis (UC) patients, correlating with disease activity. This finding suggests IRF5 may serve as a biomarker for inflammatory bowel disease (IBD) therapeutic interventions.
Area of Science:
- Gastroenterology
- Immunology
- Molecular Biology
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis (UC), involves chronic gastrointestinal inflammation with complex genetic and environmental origins.
- Current IBD therapies show variable efficacy, highlighting the need for predictive biomarkers due to disease heterogeneity.
- Over 200 genetic loci are linked to IBD, indicating a strong genetic component in its pathogenesis.
Purpose of the Study:
- To investigate the role of interferon regulatory factor 5 (IRF5) in the pathogenesis of IBD.
- To specifically assess IRF5 expression in patients with ulcerative colitis (UC).
Main Methods:
- Analysis of colon biopsies from 30 UC patients and 8 healthy controls.
- Immunostaining to quantify IRF5 expression in colonic tissues.
- Statistical correlation of IRF5-positive cells with disease activity and calprotectin levels.
Main Results:
- Significantly increased IRF5-positive macrophage-like cells were observed in inflamed UC mucosa compared to controls.
- IRF5 expression positively correlated with disease activity and calprotectin levels in IBD patients.
- Higher IRF5 levels were associated with heightened intestinal inflammation.
Conclusions:
- IRF5 expression is significantly correlated with disease activity in UC.
- IRF5 emerges as a potential novel biomarker for guiding therapeutic interventions in IBD.
- Further research is warranted to elucidate IRF5's pathogenic mechanisms and therapeutic potential in IBD.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

